OPEN END TURBO OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 05:58:44 08/07/2024 pm IST | ||
| 3.49 EUR / 3.79 EUR | +1.96% |
|
| Current month | -6.79% | ||
| 1 month | +33.21% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 08/24/08 | 3.39 | -5.04% |
| 05/24/05 | 3.57 | -5.80% |
| 04/24/04 | 3.79 | -1.81% |
| 03/24/03 | 3.86 | +9.66% |
| 02/24/02 | 3.52 | -6.38% |
Delayed Quote Börse Stuttgart
Last update July 08, 2024 at 02:47 pm IST
More quotesStatic data
| Product type | Knock-Out sin Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB4FZ9 |
| ISIN | DE000JB4FZ95 |
| Date issued | 16/10/2023 |
| Strike | 511.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 13.74 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.49 € |
|---|---|
| Lowest since issue | 2.47 € |
| Spread | 0.3 € |
| Spread % | 7.92% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474.6
USD
Average target price
468.3
USD
Spread / Average Target
-1.33%
- Stock Market
- Certificates
- Certificat
